Recalls, market withdrawals, & safety alerts > bristol-myers squibb initiates a nationwide voluntary recall of coumadin (r) 1 mg tablet blister packs
Home 1 > Safety 2 > Recalls, Market Withdrawals, & Safety Alerts 3
Recall -- Firm Press Release
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a
service to consumers, the media, and other interested parties. FDA does not endorse either the product or the
Bristol-Myers Squibb Initiates a Nationwide Voluntary Recall of Coumadin® 1 mg Tablet Blister
-Recall Involves 1 mg Physician Sample Blister Packs and 1 mg Hospital Blister Packs Only-
FOR IMMEDIATE RELEASE
-- July 12, 2010 - Bristol-Myers Squibb initiates a voluntary recall of 3 lots of
physician sample blister packs of Coumadin® 1 mg tablets and 5 lots, of Coumadin 1 mg tablet hospital unit
dose (HUD) blister packs. The following lot numbers are included in this recall: Physician Sample Blister Packs:
Lot# 9A48931A, 9A48931B, 9A48931C, expiration January 2012; HUD Blister Pack: Lot# 8F34006B, 8K44272A,
8K46168A, 9F44437A and 9K58012B with expiry dates between June 2011 and November 2012. The recall is a
precautionary measure based upon the company’s determination that some of the tablets, over time, may not
meet specification for isopropanol. Isopropanol is used to maintain the active ingredient, Coumadin, in the
crystalline state, and could affect the therapeutic levels of the active ingredient.
Coumadin is prescribed to treat or prevent blood clots. A decrease of active ingredient may increase the risk of
clots which could lead to heart attack or stroke and if there is too much active ingredient, there is an increased
risk of bleeding.
The recall only involves Coumadin 1 mg tablet blister-packs distributed in the U.S. This recall does not involve
Coumadin 1 mg supplied in bottles or any other strengths and dosage forms of the product. Patients who may
have product from the subject lots should contact their physicians to ensure that their anticoagulation therapy is
To date, the company has not received any reports of adverse events related to this issue. Bristol-Myers Squibb
is committed to ensuring patient safety and is working to resolve this issue quickly and appropriately. The
company has notified the U.S. Food and Drug Administration (FDA), and has issued recall communications to allphysicians 9 and other customers 10 involved.
Any adverse reactions may also be reported to the FDA's MedWatch Program by fax at 1-800-FDA-0178, by mail
at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website atwww.fda.gov 11.
Healthcare professionals and customers may call the following for assistance if they have further questions
RSS Feed for FDA Recalls Information 12 [what's this? 13]
Links on this page:
DISFUNCIÓN ERÉCTIL ERECTILE DYSFUNCTION DR. EDUARDO ÁLVAREZ A. Departamento de Urología. Clínica Las Condes. email@example.com La Disfunción Eréctil antes de los años 70 despertaba escaso Before the 70´ the erectile dysfunction had little clinical interés clínico. Los pacientes raramente consultaban y los mé- interest. There were no effective study resources a
Rationale and Design of the CAROLINA Trial: An Active Comparator CARdiOvascular Outcome Study of the DPP-4 InhibitorLINAgliptin in Patients With Type 2 Diabetes at High Cardiovascular RiskJulio Rosenstock1, Nikolaus Marx2, Steven E. Kahn3, Bernard Zinman4, John J. Kastelein5, John Lachin6, Erich Bluhmki7, Arno Schlosser8, Dietmar Neubacher7, Sanjay Patel9, Odd Erik Johansen10, Hans-Jüergen Wo